注意欠陥多動性障害の市場：治療法、患者タイプ、用途別-2025-2030年の世界予測

注意欠陥多動性障害市場は、2023年に149億9,000万米ドルと評価され、2024年には156億1,000万米ドルに達すると予測され、CAGR 4.18％で成長し、2030年には199億8,000万米ドルに達すると予測されています。

注意欠陥多動性障害（ADHD）は、不注意、多動性、衝動性の症状を特徴とする神経発達障害であり、子どもの教育成績や成人の職業的生産性に影響を与えます。ADHDの市場分析範囲には、医薬品、行動療法、デジタル療法が含まれ、認知度の上昇、診断手順の改善、有病率の増加が原動力となっています。ADHD治療の必要性と応用は、患者の生活の質を高めることに基づいており、家庭、教育機関、職場にとって極めて重要です。最終用途の範囲には、小児および成人の患者、教育現場、ヘルスケアプロバイダー、研究所などが含まれます。同市場は、罹患率の増加、洗練された治療オプション、メンタルヘルスニーズに対する社会的認知の高まりによって推進されています。主な成長要因としては、遠隔医療サービス、個別化医療、政府のヘルスケア・イニシアチブなどの技術的進歩が挙げられます。好機としては、デジタル治療や非侵襲的ニューロフィードバック療法などの新規治療が受け入れられつつあることが挙げられます。市場関係者は、これらの新技術の研究開発に投資し、ヘルスケア施設や学術機関との提携を拡大し、製品を広く普及させることが推奨されます。活気ある成長軌道にもかかわらず、スティグマ化、地域によって異なる診断基準、高額な治療費といった課題は依然として残っています。さらに、新薬承認のための規制上のハードルや、保険適用拡大の複雑さが障壁となっています。AIを活用した診断ツール、費用対効果の高い治療提供モデル、スティグマと闘うための啓発キャンペーンなど、イノベーション分野の開拓が必要です。ADHD市場は本質的にダイナミックであり、ヘルスケア、テクノロジー、社会文化の各傾向が交錯して形成されています。患者中心のイノベーションと戦略的パートナーシップへの投資により、これらの領域の融合点に位置する企業は、この分野で成功する可能性が高いです。企業は、市場の潜在力を効果的に獲得するために、進化する規制基準や消費者の期待に迅速に対応できる適応性を維持する必要があります。

市場力学：急速に進化する注意欠陥多動性障害市場の主要市場インサイトを公開

注意欠陥多動性障害市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。こうした動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 世界中の小児および成人における注意欠陥多動性障害の有病率の増加
  • 注意欠陥多動性障害の早期発見のための診断ツールと技術の進歩
  • 注意欠陥多動性障害に対する親や教育者の認識と教育イニシアチブの高まり
  • 注意欠陥多動性障害市場における革新的治療法の研究開発活動の急増
• 市場抑制要因
  • ADHDの専門知識を有する有資格のメンタルヘルス専門家の不足による診断や治療の遅れや誤り
• 市場機会
  • さまざまな年齢層のADHD患者の症状別緩和をターゲットとした革新的な医薬品製剤
  • ADHDの子どもの学習経験を高めるために設計された、カスタマイズされた教育プログラムやツール
  • 生産性とメンタルヘルス改善に焦点を当てた、成人ADHD患者向けの職場適応ソリューション
• 市場の課題
  • ADHDの診断と治療にかかる高額な費用と保険適用範囲の狭さが、患者にとってのアクセシビリティを低下させています。

ポーターの5つの力：注意欠陥多動性障害市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：注意欠陥多動性障害市場における外部からの影響の把握

外部マクロ環境要因は、注意欠陥多動性障害市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析注意欠陥多動性障害市場における競合情勢の把握

注意欠陥多動性障害市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス注意欠陥多動性障害市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、注意欠陥多動性障害市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨注意欠陥多動性障害市場における成功への道筋を描く

注意欠陥多動性障害市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 世界中の子供と大人の間で注意欠陥多動性障害の蔓延が増加
    • 注意欠陥多動性障害の早期検出のための診断ツールと技術の進歩
    • 親や教育者の間で注意欠陥多動性障害に関する意識と教育活動が高まっている
    • 革新的な治療法の研究開発活動の急増注意欠陥多動性障害の市場
  • 抑制要因
    • ADHDの専門知識を持つ有資格のメンタルヘルス専門家の不足により、診断や治療が遅れたり、誤った治療が行われたりする
  • 機会
    • ADHDのさまざまな年齢層の症状に特化した緩和を目的とした革新的な医薬品製剤
    • ADHDの子どもの学習体験を向上させるために設計されたカスタマイズされた教育プログラムとツール
    • 生産性とメンタルヘルスの改善に重点を置いた、成人向けADHD職場適応ソリューション
  • 課題
    • ADHDの診断と治療にかかる高額な費用と限られた保険適用により、患者のアクセスが制限されています。
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTLE分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 注意欠陥多動性障害の市場セラピー

• 薬物療法
  • 非刺激性
  • 覚醒剤
• 心理療法
  • 行動療法
  • 認知行動療法
  • 家族療法
  • ソーシャルスキルトレーニング

第7章 注意欠陥多動性障害の市場患者タイプ別

• 入院患者
• 外来患者

第8章 注意欠陥多動性障害の市場：用途別

• 注意欠陥障害
• 多動性障害

第9章 南北アメリカの注意欠陥多動性障害の市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域の注意欠陥多動性障害の市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの注意欠陥多動性障害の市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• 1. Akili Interactive Labs, Inc.
• 2. Austedo Pharmaceuticals
• 3. Cingulate Therapeutics, LLC
• 4. Eli Lilly and Company
• 5. Ironshore Pharmaceuticals Inc.
• 6. Janssen Pharmaceuticals, Inc.
• 7. KemPharm, Inc.
• 8. Medice Arzneimittel Putter GmbH & Co. KG
• 9. Neos Therapeutics, Inc.
• 10. NeuroSigma, Inc.
• 11. NLS Pharmaceutics AG
• 12. Novartis AG
• 13. Otsuka Pharmaceutical Co., Ltd.
• 14. Pfizer Inc.
• 15. Shire Plc
• 16. Sunovion Pharmaceuticals Inc.
• 17. Supernus Pharmaceuticals, Inc.
• 18. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

• FIGURE 1. ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET RESEARCH PROCESS
• FIGURE 2. ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET DYNAMICS
• TABLE 7. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY NON-STIMULANTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY STIMULANTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY BEHAVIORAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY COGNITIVE BEHAVIORAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY FAMILY THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY SOCIAL SKILLS TRAINING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY IN-PATIENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY OUT-PATIENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY ATTENTION DEFICIT DISORDER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY HYPERACTIVE DISORDER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. AMERICAS ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 25. AMERICAS ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 26. AMERICAS ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 27. AMERICAS ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 28. AMERICAS ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 29. AMERICAS ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 30. ARGENTINA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 31. ARGENTINA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 32. ARGENTINA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 33. ARGENTINA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 34. ARGENTINA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 35. BRAZIL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 36. BRAZIL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 37. BRAZIL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 38. BRAZIL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 39. BRAZIL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 40. CANADA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 41. CANADA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 42. CANADA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 43. CANADA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 44. CANADA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 45. MEXICO ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 46. MEXICO ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 47. MEXICO ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 48. MEXICO ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 49. MEXICO ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 50. UNITED STATES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 51. UNITED STATES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 52. UNITED STATES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 53. UNITED STATES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 54. UNITED STATES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 55. UNITED STATES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 56. ASIA-PACIFIC ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 57. ASIA-PACIFIC ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 58. ASIA-PACIFIC ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 59. ASIA-PACIFIC ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 60. ASIA-PACIFIC ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 61. ASIA-PACIFIC ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 62. AUSTRALIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 63. AUSTRALIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 64. AUSTRALIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 65. AUSTRALIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 66. AUSTRALIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 67. CHINA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 68. CHINA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 69. CHINA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 70. CHINA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 71. CHINA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 72. INDIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 73. INDIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 74. INDIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 75. INDIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 76. INDIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 77. INDONESIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 78. INDONESIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 79. INDONESIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 80. INDONESIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 81. INDONESIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 82. JAPAN ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 83. JAPAN ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 84. JAPAN ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 85. JAPAN ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 86. JAPAN ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 87. MALAYSIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 88. MALAYSIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 89. MALAYSIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 90. MALAYSIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 91. MALAYSIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 92. PHILIPPINES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 93. PHILIPPINES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 94. PHILIPPINES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 95. PHILIPPINES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 96. PHILIPPINES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 97. SINGAPORE ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 98. SINGAPORE ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 99. SINGAPORE ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 100. SINGAPORE ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 101. SINGAPORE ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 102. SOUTH KOREA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 103. SOUTH KOREA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 104. SOUTH KOREA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 105. SOUTH KOREA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 106. SOUTH KOREA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 107. TAIWAN ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 108. TAIWAN ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 109. TAIWAN ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 110. TAIWAN ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 111. TAIWAN ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 112. THAILAND ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 113. THAILAND ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 114. THAILAND ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 115. THAILAND ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 116. THAILAND ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 117. VIETNAM ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 118. VIETNAM ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 119. VIETNAM ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 120. VIETNAM ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 121. VIETNAM ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 122. EUROPE, MIDDLE EAST & AFRICA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 123. EUROPE, MIDDLE EAST & AFRICA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 124. EUROPE, MIDDLE EAST & AFRICA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 125. EUROPE, MIDDLE EAST & AFRICA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 126. EUROPE, MIDDLE EAST & AFRICA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 127. EUROPE, MIDDLE EAST & AFRICA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 128. DENMARK ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 129. DENMARK ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 130. DENMARK ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 131. DENMARK ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 132. DENMARK ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 133. EGYPT ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 134. EGYPT ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 135. EGYPT ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 136. EGYPT ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 137. EGYPT ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 138. FINLAND ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 139. FINLAND ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 140. FINLAND ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 141. FINLAND ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 142. FINLAND ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 143. FRANCE ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 144. FRANCE ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 145. FRANCE ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 146. FRANCE ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 147. FRANCE ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 148. GERMANY ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 149. GERMANY ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 150. GERMANY ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 151. GERMANY ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 152. GERMANY ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 153. ISRAEL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 154. ISRAEL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 155. ISRAEL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 156. ISRAEL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 157. ISRAEL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 158. ITALY ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 159. ITALY ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 160. ITALY ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 161. ITALY ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 162. ITALY ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 163. NETHERLANDS ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 164. NETHERLANDS ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 165. NETHERLANDS ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 166. NETHERLANDS ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 167. NETHERLANDS ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 168. NIGERIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 169. NIGERIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 170. NIGERIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 171. NIGERIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 172. NIGERIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 173. NORWAY ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 174. NORWAY ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 175. NORWAY ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 176. NORWAY ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 177. NORWAY ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 178. POLAND ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 179. POLAND ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 180. POLAND ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 181. POLAND ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 182. POLAND ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 183. QATAR ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 184. QATAR ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 185. QATAR ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 186. QATAR ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 187. QATAR ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 188. RUSSIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 189. RUSSIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 190. RUSSIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 191. RUSSIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 192. RUSSIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 193. SAUDI ARABIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 194. SAUDI ARABIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 195. SAUDI ARABIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 196. SAUDI ARABIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 197. SAUDI ARABIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 198. SOUTH AFRICA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 199. SOUTH AFRICA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 200. SOUTH AFRICA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 201. SOUTH AFRICA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 202. SOUTH AFRICA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 203. SPAIN ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 204. SPAIN ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 205. SPAIN ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 206. SPAIN ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 207. SPAIN ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 208. SWEDEN ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 209. SWEDEN ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 210. SWEDEN ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 211. SWEDEN ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 212. SWEDEN ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 213. SWITZERLAND ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 214. SWITZERLAND ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 215. SWITZERLAND ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 216. SWITZERLAND ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 217. SWITZERLAND ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 218. TURKEY ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 219. TURKEY ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 220. TURKEY ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 221. TURKEY ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 222. TURKEY ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 223. UNITED ARAB EMIRATES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 224. UNITED ARAB EMIRATES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 225. UNITED ARAB EMIRATES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 226. UNITED ARAB EMIRATES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 227. UNITED ARAB EMIRATES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 228. UNITED KINGDOM ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 229. UNITED KINGDOM ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 230. UNITED KINGDOM ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 231. UNITED KINGDOM ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 232. UNITED KINGDOM ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 233. ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 234. ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET, FPNV POSITIONING MATRIX, 2023

The Attention Deficit Hyperactivity Disorder Market was valued at USD 14.99 billion in 2023, expected to reach USD 15.61 billion in 2024, and is projected to grow at a CAGR of 4.18%, to USD 19.98 billion by 2030.

Attention Deficit Hyperactivity Disorder (ADHD) is a neurodevelopmental disorder characterized by symptoms of inattention, hyperactivity, and impulsivity, impacting children's educational performance and adults' professional productivity. The scope of market analysis for ADHD encompasses pharmaceuticals, behavioral therapy, and digital therapies, driven by rising awareness, improved diagnostic procedures, and increased prevalence. The necessity and application of ADHD treatments are based on enhancing patients' life quality, making them crucial for households, educational institutions, and workplaces. The end-use scope includes pediatric and adult patients, educational settings, healthcare providers, and research labs. The market is propelled by increasing incidence rates, sophisticated treatment options, and heightened societal recognition of mental health needs. Key growth influencers include technological advancements like telehealth services, personalized medicine, and government healthcare initiatives. Opportunistically, the evolving acceptance of novel treatments like digital therapeutics and non-invasive neurofeedback therapies presents unexplored opportunities. Market players are recommended to invest in R&D for these emerging technologies and expand collaborations with healthcare facilities and academic institutions for broader product dissemination. Despite the vibrant growth trajectory, challenges such as stigmatization, varied diagnosis standards across regions, and high treatment costs persist. Additionally, regulatory hurdles for new drug approvals and the complexity of gaining widespread insurance coverage pose barriers. Innovation areas ripe for exploration include AI-driven diagnostic tools, cost-effective treatment delivery models, and awareness campaigns to battle stigma. The ADHD market is inherently dynamic, shaped by intersecting healthcare, technological, and sociocultural trends. Businesses positioning themselves at the convergence of these domains with investment in patient-centered innovations and strategic partnerships stand the best chance of thriving in this sector. Companies should maintain adaptability to swiftly align with evolving regulatory standards and consumer expectations to capture market potential effectively.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Attention Deficit Hyperactivity Disorder Market

The Attention Deficit Hyperactivity Disorder Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing prevalence of attention deficit hyperactivity disorder among children and adults worldwide
  • Advancements in diagnostic tools and techniques for early detection of attention deficit hyperactivity disorder
  • Growing awareness and educational initiatives about attention deficit hyperactivity disorder among parents and educators
  • Surge in research and development activities for innovative treatment options in attention deficit hyperactivity disorder market
• Market Restraints
  • Lack of qualified mental health professionals with expertise in ADHD leading to delayed or incorrect diagnosis and treatment
• Market Opportunities
  • Innovative pharmaceutical formulations targeting symptom-specific relief for different age groups with ADHD
  • Customized educational programs and tools designed to enhance learning experiences for children with ADHD
  • Workplace accommodation solutions for adults with ADHD focusing on productivity and mental health improvement
• Market Challenges
  • High cost of ADHD diagnosis and treatment combined with limited insurance coverage reduces accessibility for patients

Porter's Five Forces: A Strategic Tool for Navigating the Attention Deficit Hyperactivity Disorder Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Attention Deficit Hyperactivity Disorder Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Attention Deficit Hyperactivity Disorder Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Attention Deficit Hyperactivity Disorder Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Attention Deficit Hyperactivity Disorder Market

A detailed market share analysis in the Attention Deficit Hyperactivity Disorder Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Attention Deficit Hyperactivity Disorder Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Attention Deficit Hyperactivity Disorder Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Attention Deficit Hyperactivity Disorder Market

A strategic analysis of the Attention Deficit Hyperactivity Disorder Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Attention Deficit Hyperactivity Disorder Market, highlighting leading vendors and their innovative profiles. These include Akili Interactive Labs, Inc., Austedo Pharmaceuticals, Cingulate Therapeutics, LLC, Eli Lilly and Company, Ironshore Pharmaceuticals Inc., Janssen Pharmaceuticals, Inc., KemPharm, Inc., Medice Arzneimittel Putter GmbH & Co. KG, Neos Therapeutics, Inc., NeuroSigma, Inc., NLS Pharmaceutics AG, Novartis AG, Otsuka Pharmaceutical Co., Ltd., Pfizer Inc., Shire Plc, Sunovion Pharmaceuticals Inc., Supernus Pharmaceuticals, Inc., and Takeda Pharmaceutical Company Limited.

Market Segmentation & Coverage

This research report categorizes the Attention Deficit Hyperactivity Disorder Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Therapies, market is studied across Pharmacotherapy and Psychotherapy. The Pharmacotherapy is further studied across Non-Stimulants and Stimulants. The Psychotherapy is further studied across Behavioral Therapy, Cognitive Behavioral Therapy, Family Therapy, and Social Skills Training.
• Based on Patient Type, market is studied across In-Patients and Out-Patients.
• Based on Application, market is studied across Attention Deficit Disorder and Hyperactive Disorder.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing prevalence of attention deficit hyperactivity disorder among children and adults worldwide
    • 5.1.1.2. Advancements in diagnostic tools and techniques for early detection of attention deficit hyperactivity disorder
    • 5.1.1.3. Growing awareness and educational initiatives about attention deficit hyperactivity disorder among parents and educators
    • 5.1.1.4. Surge in research and development activities for innovative treatment options in attention deficit hyperactivity disorder market
  • 5.1.2. Restraints
    • 5.1.2.1. Lack of qualified mental health professionals with expertise in ADHD leading to delayed or incorrect diagnosis and treatment
  • 5.1.3. Opportunities
    • 5.1.3.1. Innovative pharmaceutical formulations targeting symptom-specific relief for different age groups with ADHD
    • 5.1.3.2. Customized educational programs and tools designed to enhance learning experiences for children with ADHD
    • 5.1.3.3. Workplace accommodation solutions for adults with ADHD focusing on productivity and mental health improvement
  • 5.1.4. Challenges
    • 5.1.4.1. High cost of ADHD diagnosis and treatment combined with limited insurance coverage reduces accessibility for patients
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Attention Deficit Hyperactivity Disorder Market, by Therapies

• 6.1. Introduction
• 6.2. Pharmacotherapy
  • 6.2.1. Non-Stimulants
  • 6.2.2. Stimulants
• 6.3. Psychotherapy
  • 6.3.1. Behavioral Therapy
  • 6.3.2. Cognitive Behavioral Therapy
  • 6.3.3. Family Therapy
  • 6.3.4. Social Skills Training

7. Attention Deficit Hyperactivity Disorder Market, by Patient Type

• 7.1. Introduction
• 7.2. In-Patients
• 7.3. Out-Patients

8. Attention Deficit Hyperactivity Disorder Market, by Application

• 8.1. Introduction
• 8.2. Attention Deficit Disorder
• 8.3. Hyperactive Disorder

9. Americas Attention Deficit Hyperactivity Disorder Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Attention Deficit Hyperactivity Disorder Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Attention Deficit Hyperactivity Disorder Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Akili Interactive Labs, Inc.
• 2. Austedo Pharmaceuticals
• 3. Cingulate Therapeutics, LLC
• 4. Eli Lilly and Company
• 5. Ironshore Pharmaceuticals Inc.
• 6. Janssen Pharmaceuticals, Inc.
• 7. KemPharm, Inc.
• 8. Medice Arzneimittel Putter GmbH & Co. KG
• 9. Neos Therapeutics, Inc.
• 10. NeuroSigma, Inc.
• 11. NLS Pharmaceutics AG
• 12. Novartis AG
• 13. Otsuka Pharmaceutical Co., Ltd.
• 14. Pfizer Inc.
• 15. Shire Plc
• 16. Sunovion Pharmaceuticals Inc.
• 17. Supernus Pharmaceuticals, Inc.
• 18. Takeda Pharmaceutical Company Limited